ClearPoint faces securities fraud probe after Huntington's drug trial data disappoints, stock drops 23%.

ClearPoint Neuro is under investigation by Pomerantz LLP for potential securities fraud following a press release by its partner uniQure, which revealed that a Huntington's disease treatment failed to meet key clinical goals. This news caused ClearPoint's stock to plunge 23.12% on September 29, 2026. The investigation will determine if ClearPoint and its executives engaged in unlawful business practices. Investors affected by the stock drop are encouraged to contact the law firm for possible class action participation.

ClearPoint Neuro currently has a market cap of $324.56 million and an enterprise value of $359.15 million as of October 8, 2026, 21:12 WIB. Despite the recent sharp drop reported on September 29, the stock price on Pluang is $10.44 with a more moderate 1-day decline of 2.06%. Trading volume stands at 490,135 shares, and all recent Pluang order activity shows buying interest, with 100% of orders being buys and a typical hold time of 9 days.